InflaRx N.V. (IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics, has a couple of milestones to watch in the coming months.
The company's lead drug candidate is Vilobelimab, which is currently in a phase III trial in ulcerative pyoderma gangrenosum. The trial achieved the 30-patient recruitment milestone last November. Interim analysis for trial size adaptation or futility is expected by the end of May 2025. The enrollment period is projected to last at least two years.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.